CN110114087A - β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途 - Google Patents

β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途 Download PDF

Info

Publication number
CN110114087A
CN110114087A CN201780071597.0A CN201780071597A CN110114087A CN 110114087 A CN110114087 A CN 110114087A CN 201780071597 A CN201780071597 A CN 201780071597A CN 110114087 A CN110114087 A CN 110114087A
Authority
CN
China
Prior art keywords
seq
acid sequence
amino acid
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071597.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·卡格依
C·A·西拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feiyue Therapeutic Co
Original Assignee
Feiyue Therapeutic Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feiyue Therapeutic Co filed Critical Feiyue Therapeutic Co
Publication of CN110114087A publication Critical patent/CN110114087A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780071597.0A 2016-10-26 2017-10-26 β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途 Pending CN110114087A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413198P 2016-10-26 2016-10-26
US62/413,198 2016-10-26
PCT/US2017/058555 WO2018081437A1 (en) 2016-10-26 2017-10-26 Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

Publications (1)

Publication Number Publication Date
CN110114087A true CN110114087A (zh) 2019-08-09

Family

ID=60570180

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071597.0A Pending CN110114087A (zh) 2016-10-26 2017-10-26 β-连环蛋白作为生物标记物用于使用抗DKK-1抗体治疗癌症的用途

Country Status (14)

Country Link
US (2) US11267876B2 (https=)
EP (1) EP3532099A1 (https=)
JP (2) JP7374765B2 (https=)
KR (1) KR102701695B1 (https=)
CN (1) CN110114087A (https=)
AU (1) AU2017347822B2 (https=)
BR (1) BR112019008279A2 (https=)
CA (1) CA3041325A1 (https=)
IL (1) IL266199B2 (https=)
MA (1) MA46673A (https=)
MX (1) MX2019004940A (https=)
RU (1) RU2019115946A (https=)
SG (1) SG11201903602RA (https=)
WO (1) WO2018081437A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423459A (zh) * 2019-09-19 2022-04-29 飞跃治疗公司 Dkk-1抑制剂用于治疗癌症的用途
CN114929275A (zh) * 2019-11-22 2022-08-19 飞跃治疗公司 使用dkk-1抑制剂治疗癌症的方法
CN116350758A (zh) * 2023-03-16 2023-06-30 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
CA3128526A1 (en) 2019-02-01 2020-08-06 Board Of Regents, The University Of Texas System Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof
US20250222062A1 (en) * 2022-03-24 2025-07-10 The Translational Genomics Research Institute Peptide inhibitors targeting the tbl1-beta-catenin complex

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193449A1 (en) * 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for DKK-1
US20100260754A1 (en) * 2009-04-10 2010-10-14 Eli Lilly And Company Dkk-1 antibodies
US20160011201A1 (en) * 2013-02-27 2016-01-14 Daiichi Sankyo Company, Limited Method For Predicting Responsiveness To Compound Inhibiting MAPK Signal Transduction Pathway
CN105829547A (zh) * 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
CN102421798A (zh) 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN103608037B (zh) * 2011-02-01 2016-04-13 香港大学 抗dkk1单克隆抗体用于治疗肝癌的用途
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
BR112022004851A2 (pt) 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193449A1 (en) * 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for DKK-1
US20100260754A1 (en) * 2009-04-10 2010-10-14 Eli Lilly And Company Dkk-1 antibodies
US20160011201A1 (en) * 2013-02-27 2016-01-14 Daiichi Sankyo Company, Limited Method For Predicting Responsiveness To Compound Inhibiting MAPK Signal Transduction Pathway
CN105829547A (zh) * 2013-12-02 2016-08-03 昂科梅德制药有限公司 与Wnt途径抑制剂有关的预测性生物标记物的鉴别

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHANNA C.BENDELL等: "http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.111", 《百度》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423459A (zh) * 2019-09-19 2022-04-29 飞跃治疗公司 Dkk-1抑制剂用于治疗癌症的用途
CN114929275A (zh) * 2019-11-22 2022-08-19 飞跃治疗公司 使用dkk-1抑制剂治疗癌症的方法
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
CN116350758A (zh) * 2023-03-16 2023-06-30 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用
CN116350758B (zh) * 2023-03-16 2024-08-06 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用

Also Published As

Publication number Publication date
WO2018081437A1 (en) 2018-05-03
CA3041325A1 (en) 2018-05-03
JP7374765B2 (ja) 2023-11-07
KR20190085935A (ko) 2019-07-19
SG11201903602RA (en) 2019-05-30
RU2019115946A (ru) 2020-11-27
EP3532099A1 (en) 2019-09-04
US12319730B2 (en) 2025-06-03
IL266199B1 (en) 2024-10-01
AU2017347822A1 (en) 2019-05-09
AU2017347822B2 (en) 2025-01-16
RU2019115946A3 (https=) 2021-01-26
US20220289831A1 (en) 2022-09-15
JP2023133432A (ja) 2023-09-22
IL266199B2 (en) 2025-02-01
MX2019004940A (es) 2019-09-26
KR102701695B1 (ko) 2024-08-30
US20190284264A1 (en) 2019-09-19
BR112019008279A2 (pt) 2019-07-09
IL266199A (en) 2019-06-30
JP2019533693A (ja) 2019-11-21
US11267876B2 (en) 2022-03-08
MA46673A (fr) 2019-09-04

Similar Documents

Publication Publication Date Title
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US20220162332A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
JP7374765B2 (ja) 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用
KR102017070B1 (ko) 치료 펩티드
EP3137502B1 (en) Humanized antibodies against ceacam1
TW201734044A (zh) 抗－ｍｅｔ抗體及其使用方式
CN110382532A (zh) 抗g-csf抗体及其用途
CN114929275A (zh) 使用dkk-1抑制剂治疗癌症的方法
CN112739716A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP2024533439A (ja) 併用療法
KR20170023414A (ko) 간세포 암종을 위한 항-ｖｅｇｆｒ2 항체 요법
CN112538117B (zh) 抗人癌胚抗原抗体及其编码基因和应用
TW202438525A (zh) Lair-1促效性抗體及其使用方法
HK40109234A (zh) 用於治疗癌症的方法和组合物
WO2024223299A2 (en) Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
TW201729827A (zh) 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190809